# TRex Bio, Inc. (TRXB)

> Source: Nexqual · https://nexqual.com/TRXB · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, TRex Bio, Inc. (TRXB), nexqual.com/TRXB" · informational, not investment advice.

**Price:** USD 14.16 (+4.89% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 13.5 · day 13.5–14.33 · 52w 13.21–15.5 · market cap $389M · NMS

## Key facts
- Analysts: None.
- Total return with dividends: 1Y +1.1% vs S&P 500 +18.1%; 5Y +1.1% vs S&P 500 +85.1%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2026-10-09) | 5Y (from 2026-10-05) |
|---|---|---|
| Total return | +1.1% | +1.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 52.4% | 5.8% |
| Max drawdown | -3.8% (Oct 2026→Oct 2026) | +0.0% (→) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/TRXB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt